FDA Clearance Tracker · P230036-S010
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Apr 16, 2025
Approved
Time to decision
27 days
Received Mar 20, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230036-S010
- Device name
- Esprit BTK Everolimus Eluting Resorbable Scaffold System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Santa Clara, CA
- Received
- Mar 20, 2025
- Decided
- Apr 16, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P230036
Device type
- Device type
- Scaffold, infrapopliteal, absorbable (NXW)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the Esprit BTK-PAS: New Enrollment Study submitted in P230036/S010.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.